Narcolepsy Associated with Pandemrix Vaccine

Current Neurology and Neuroscience Reports

Volumn 18, Issue 7, 2018, Pages

  Sarkanen, Tomi ^a,b   Alakuijala, Anniina ^b,c   Julkunen, Ilkka ^d   Partinen, Markku ^b,e  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e Vitalmed Research Center   (Finland)

Author keywords

H1N1 vaccination; Hypocretin; Narcolepsy; Orexin; Pandemrix; Vaccines

Indexed keywords

5' NUCLEOTIDASE CYTOSOLIC IA; ANTIBODY; AUTOANTIBODY; HLA ANTIGEN; HLA DPA1 ANTIGEN; HLA DQB1 ANTIGEN; IMMUNOGLOBULIN; INFLUENZA VACCINE; METHYLPHENIDATE; METHYLPREDNISOLONE; METHYLTRANSFERASE LIKE 22; MODAFINIL; NEUREXIN 1; OREXIN; OXYBATE SODIUM; PROSTAGLANDIN D2 RECEPTOR; PROSTAGLANDIN RECEPTOR; PROTEIN; RITUXIMAB; TRIBBLES 2 ANTIBODY; UNCLASSIFIED DRUG; VIRUS NUCLEOPROTEIN; HCRT PROTEIN, HUMAN;

CHKB GENE; CLINICAL FEATURE; CPT1B GENE; CROSS REACTION; CYTOTOXICITY; DISEASE ASSOCIATION; GENE; GENETIC POLYMORPHISM; HUMAN; HYPOCRETIN DEFICIENCY; IDIOPATHIC NARCOLEPSY; IMMUNOTHERAPY; INCIDENCE; INFLAMMATION; INFLUENZA VACCINATION; MOLECULAR MIMICRY; NARCOLEPSY; NERVE CELL LESION; PATHOPHYSIOLOGY; REVIEW; STREPTOCOCCUS INFECTION; ADOLESCENT; ANIMAL; CHILD; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); METABOLISM;

ADOLESCENT; ANIMALS; CHILD; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NARCOLEPSY; OREXINS;

EID: 85048196122     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-018-0851-5     Document Type: Review

References (75)

1. American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.
2. •• Sarkanen T, Alakuijala A, Dauvilliers Y, Partinen M. Incidence of narcolepsy after H1N1 influenza and vaccinations: systematic review and meta-analysis. Sleep Med Rev. 2017; https://doi.org/10.1016/j.smrv.2017.06.006. A comprehensive review and meta-analysis of the observational studies reporting an association with Pandemrix and narcolepsy. In addition, biases affecting the risk and lack of an association with other vaccines and narcolepsy are discussed.
3. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. Narcolepsy as an autoimmune disease: the role of H1N1 infection and vaccination. Lancet Neurol. 2014;13(6):600–13.
4. Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880–7.
5. European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation). Stockholm 2012. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Vaesco%20report%20FINAL%20with%20cover.pdf. Accessed 13 Nov 2017.
6. GlaxoSmithKline. GSK Public policy positions. Pandemic preparedness. 2014. https://www.gsk.com/media/2951/pandemic-preparedness-policy.pdf. Accessed 13 Nov 2017.
7. •• Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One. 2012;7(3):e33536. The first epidemiological study reporting an increased incidence of narcolepsy after vaccination with Pandemrix.
8. Medical Products Agency. A registry based comparative cohort study in four Swedish counties of the risk for narcolepsy after vaccination with Pandemrix—a first and preliminary report. 2011. https://lakemedelsverket.se/upload/nyheter/2011/PandemrixRegReport110328.pdf. Accessed 13 Nov 2017.
9. Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain. 2013;136(Pt 8):2486–96.
10. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med. 2013;14(9):867–71.
11. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ. 2013;346:f794.
12. O’Flanagan D, Barret AS, Foley M, Cotter S, Bonner C, Crowe C, et al. Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. Euro Surveill. 2014;19(17):15–25.
13. Oberle D, Pavel J, Mayer G, Geisler P, Keller-Stanislawski B. Retrospective multicenter matched case-control study on the risk factors for narcolepsy with special focus on vaccinations (including pandemic influenza vaccination) and infections in Germany. Sleep Med. 2017;34:71–83.
14. Jokinen J, Nohynek H, Honkanen J, Vaarala O, Partinen M, Hublin C et al. Pandemiarokotteen ja narkolepsian yhteys aikuisilla - Varmennettuihin rekisteritietoihin perustuva kohorttitutkimus. 2013. http://urn.fi/URN:ISBN:978-952-245-921-3. Accessed 13 Nov 2017.
15. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med. 2014;275(2):172–90.
16. Stowe J, Miller E, Andrews N, Kosky C, Leschziner G, Shneerson JM, et al. Risk of narcolepsy after AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in adults: a case-coverage study in England. Sleep. 2016;39(5):1051–7.
17. Jokinen J, Nohynek H, Vaarala O, Kilpi T. Pandemiarokotteen ja narkolepsian yhteys - vuoden 2012 loppuun mennessä kertyneisiin rekisteritietoihin perustuva seurantaraportti. 2014. http://urn.fi/URN:ISBN:978-952-302-255-3. Accessed 13 Nov 2017.
18. •• Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, Hublin C, Linna M, Olsen P, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One. 2012;7(3):e33723. The first article reporting the clinical picture and increased incidence of narcolepsy after vaccination with Pandemrix in the Nordic countries.
19. Verstraeten T, Cohet C, Santos GD, Ferreira GL, Bollaerts K, Bauchau V, et al. Pandemrix and narcolepsy: a critical appraisal of the observational studies. Hum Vaccin Immunother. 2016;12(1):187–93.
20. Bollaerts K, Shinde V, Dos Santos G, Ferreira G, Bauchau V, Cohet C, et al. Application of probabilistic multiple-bias analyses to a cohort- and a case-control study on the association between Pandemrix and narcolepsy. PLoS One. 2016;11(2):e0149289.
21. Sturkenboom MCJM. The narcolepsy-pandemic influenza story: can the truth ever be unraveled? Vaccine. 2015;33(Supplement 2):B6–B13.
22. • Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol. 2011;70(3):410–7. The authors report a 3-fold increase of narcolepsy in the Beijing area in China where no pandemic vaccines were used. A similar finding was seen in the Shanghai area, but not in any other country.
23. Han F, Lin L, Li J, Dong XS, Mignot E. Decreased incidence of childhood narcolepsy 2 years after the 2009 H1N1 winter flu pandemic. Ann Neurol. 2013;73(4):560.
24. Wu H, Zhuang J, Stone WS, Zhang L, Zhao Z, Wang Z, et al. Symptoms and occurrences of narcolepsy: a retrospective study of 162 patients during a 10-year period in eastern China. Sleep Med. 2014;15(6):607–13.
25. Choe YJ, Bae GR, Lee DH. No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: an ecological study. Vaccine. 2012;30(52):7439–42.
26. Gil Cuesta J, Aavitsland P, Englund H, Gudlaugsson O, Hauge SH, Lyytikainen O, et al. Pandemic vaccination strategies and influenza severe outcomes during the influenza A(H1N1)pdm09 pandemic and the post-pandemic influenza season: the Nordic experience. Euro Surveill. 2016; 10.2807/1560-7917.ES.2016.21.16.30208.
27. Van Effelterre T, Dos Santos G, Shinde V. Twin peaks: A/H1N1 pandemic influenza virus infection and vaccination in Norway, 2009-2010. PLoS One. 2016;11(3):e0151575.
28. Melen K, Partinen M, Tynell J, Sillanpaa M, Himanen SL, Saarenpaa-Heikkila O, et al. No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland. PLoS One. 2013;8(8):e68402.
29. Innis B, Boutet P. Comment on: Melen K, Partinen M, Tynell J, Sillanpaa M, Himanen S-L, et al. No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after pandemrix vaccination campaign in Finland. PLoS One. 2014. http://journals.plos.org/plosone/article/comment?id=10.1371/annotation/eab58001-4872-4b9d-94d7-c85a16b4b6d6. Accessed 13 Nov 2017.
30. •• Vaarala O, Vuorela A, Partinen M, Baumann M, Freitag TL, Meri S, et al. Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for Pandemrix-associated narcolepsy risk. PLoS One. 2014;9(12):e114361. A study reporting differences in nucleoprotein (NP) of the viral component in Pandemrix and Arepanrix. Furthermore, increased antibody response against NP was seen in subjects with the HLA DQB1*06:02 narcolepsy risk allele.
31. Ahmed SS, Volkmuth W, Duca J, Corti L, Pallaoro M, Pezzicoli A, et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med. 2015;7(294):294ra105.
32. Tesoriero C, Codita A, Zhang MD, Cherninsky A, Karlsson H, Grassi-Zucconi G, et al. H1N1 influenza virus induces narcolepsy-like sleep disruption and targets sleep-wake regulatory neurons in mice. Proc Natl Acad Sci U S A. 2016;113(3):E368–77.
33. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and g protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573–85.
34. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A. 1998;95(1):322–7.
35. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med. 2000;6(9):991–7.
36. Julkunen I, Partinen M. Neuroimmunology: disease mechanisms in narcolepsy remain elusive. Nat Rev Neurol. 2014;10(11):616–7.
37. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev. 2005;9(4):269–310.
38. • Tafti M, Hor H, Dauvilliers Y, Lammers GJ, Overeem S, Mayer G, et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep. 2014;37(1):19–25. A large genome-wide association (GWAS) study with over 1200 narcolepsy patients and 3500 controls. It was shown that the majority of the genetic risk of narcolepsy is explained by the HLA DQB1 locus only. HLA DQB1*06:02 positive individuals carry a 251-fold increased risk of developing narcolepsy.
39. Hor H, Bartesaghi L, Kutalik Z, Vicario JL, de Andres C, Pfister C, et al. A missense mutation in myelin oligodendrocyte glycoprotein as a cause of familial narcolepsy with cataplexy. Am J Hum Gen. 2011;89(3):474–9.
40. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, Lin X, et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Gen. 2001;68(3):686–99.
41. • Ollila HM, Ravel JM, Han F, et al. HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy. Am J Hum Genet. 2015;96:136–46. One of the first reports to find HLA class I associations in narcolepsy.
42. • Tafti M, Lammers GJ, Dauvilliers Y, et al. Narcolepsy-associated HLA class I alleles implicate cell-mediated cytotoxicity. Sleep. 2016;39:581–7. One of the first reports to find HLA class I associations in narcolepsy.
43. Aran A, Lin L, Nevsimalova S, Plazzi G, Hong SC, Weiner K, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep. 2009;32(8):979–83.
44. Haggmark-Manberg A, Zandian A, Forsstrom B, Khademi M, Lima Bomfim I, Hellstrom C, et al. Autoantibody targets in vaccine-associated narcolepsy. Autoimmunity. 2016;49(6):421–33.
45. Saariaho AH, Vuorela A, Freitag TL, Pizza F, Plazzi G, Partinen M, et al. Autoantibodies against ganglioside GM3 are associated with narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type influenza virus. J Autoimmun. 2015;63:68–75.
46. Cvetkovic-Lopes V, Bayer L, Dorsaz S, Maret S, Pradervand S, Dauvilliers Y, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest. 2010;120(3):713–9.
47. Kawashima M, Lin L, Tanaka S, Jennum P, Knudsen S, Nevsimalova S, et al. Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep. 2010;33(7):869–74.
48. Katzav A, Arango MT, Kivity S, Tanaka S, Givaty G, Agmon-Levin N, et al. Passive transfer of narcolepsy: anti-TRIB2 autoantibody positive patient IgG causes hypothalamic orexin neuron loss and sleep attacks in mice. J Autoimmun. 2013;45:24–30.
49. Lind A, Ramelius A, Olsson T, Arnheim-Dahlstrom L, Lamb F, Khademi M, et al. A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010. J Autoimmun. 2014;50:99–106.
50. Tanaka S, Honda Y, Honda M, Yamada H, Honda K, Kodama T. Anti-tribbles pseudokinase 2 (TRIB2)-immunization modulates hypocretin/orexin neuronal functions. Sleep. 2017; 10.1093/sleep/zsw036.
51. Goodfellow JA, Willison HJ. Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Curr Opin Neurol. 2016;29(5):572–80.
52. Overeem S, Geleijns K, Garssen MP, Jacobs BC, van Doorn PA, Lammers GJ. Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neurosci Lett. 2003;341(1):13–6.
53. • Bergman P, Adori C, Vas S, Kai-Larsen Y, Sarkanen T, Cederlund A, et al. Narcolepsy patients have antibodies that stain distinct cell populations in rat brain and influence sleep patterns. Proc Natl Acad Sci U S A. 2014;111(35):E3735–44. In this study, 27% of narcolepsy patients showed autoantibodies against three different neuronal structures in immunohistochemical stainings on rat brain. Although staining against hypocretin neurons was not seen, autoantibodies against hypothalamic NEI/αMSH neurons were found. Passive transfer of sera from NEI/αMSH-positive subject into a rat brain produced disturbed REM and slow wave sleep patterns.
54. Montplaisir J, Petit D, Quinn M-J, Ouakki M, Deceuninck G, Desautels A, et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One. 2014;9(9):e108489.
55. Jacob L, Leib R, Ollila HM, Bonvalet M, Adams CM, Mignot E. Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015;47:44–57.
56. Luo G, Lin L, Jacob L, Bonvalet M, Ambati A, Plazzi G, et al. Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases. PLoS ONE. 12(12):e0187305. 10.1371/journal.pone.0187305.
57. Giannoccaro MP, Waters P, Pizza F, Liguori R, Plazzi G, Vincent A. Antibodies against hypocretin receptor 2 are rare in narcolepsy. Sleep. 2017;40 10.1093/sleep/zsw056.
58. • Zandian A, Forsstrom B, Haggmark-Manberg A, Schwenk JM, Uhlen M, Nilsson P, et al. Whole-proteome peptide microarrays for profiling autoantibody repertoires within multiple sclerosis and narcolepsy. J Proteome Res. 2017;16(3):1300–14. The authors presented a novel method for screening autoantibodies, namely high-density peptide arrays. They recognized a potential new autoantigen neurexin 1 in narcolepsy.
59. • Sadam H, Pihlak A, Kivil A, Pihelgas S, Jaago M, Adler P, et al. Prostaglandin D2 receptor DP1 antibodies predict vaccine-induced and spontaneous narcolepsy type 1: large-scale study of antibody profiling. EBioMedicine. 2018;29:47–59. The authors describe a potentially new autoantigen prostaglandin D2 receptor against which narcolepsy patient have developed autoantibodies.
60. Ambati A, Poiret T, Svahn BM, Valentini D, Khademi M, Kockum I, et al. Increased beta-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases. J Intern Med. 2015;278(3):264–76.
61. Soriano A, Nesher G, Shoenfeld Y. Predicting post-vaccination autoimmunity: who might be at risk? Pharmacol Res. 2015;92:18–22.
62. Martinez-Orozco FJ, Vicario JL, Villalibre-Valderrey I, De Andres C, Fernandez-Arquero M, Peraita-Adrados R. Narcolepsy with cataplexy and comorbid immunopathological diseases. J Sleep Res. 2014;23(4):414–9.
63. Barateau L, Lopez R, Arnulf I, Lecendreux M, Franco P, Drouot X, et al. Comorbidity between central disorders of hypersomnolence and immune-based disorders. Neurology. 2017;88(1):93–100.
64. Pizza F, Peltola H, Sarkanen T, Moghadam KK, Plazzi G, Partinen M. Childhood narcolepsy with cataplexy: comparison between post-H1N1 vaccination and sporadic cases. Sleep Med. 2013;15(2):262–5.
65. • Sarkanen T, Alakuijala A, Partinen M. Clinical course of H1N1-vaccine-related narcolepsy. Sleep Med. 2016;19:17–22. The first longitudinal study of the clinical phenotype of Pandemrix-related narcolepsy. The symptoms of narcolepsy and severity of the disease seem very heterogeneous.
66. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology. 2013;80(14):1315–21.
67. Medical Products Agency. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations—results of a case inventory study by the MPA in Sweden during 2009–2010. https://lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf. Accessed 13 Nov 2017.
68. Winstone AM, Stellitano L, Verity C, Andrews N, Miller E, Stowe J, et al. Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England. Dev Med Child Neurol. 2014;56(11):1117–23.
69. ECDC comment. Update on narcolepsy cases associated with Pandemrix vaccination in 2009 in the Netherlands. https://ecdc.europa.eu/en/news-events/update-narcolepsy-cases-associated-pandemrix-vaccination-2009-netherlands. Accessed 13 Nov 2017.
70. Alakuijala A, Sarkanen T, Partinen M. Polysomnographic and actigraphic characteristics of patients with H1N1-vaccine-related and sporadic narcolepsy. Sleep Med. 2015;16(1):39–44.
71. Knudsen S, Biering-Sorensen B, Kornum BR, Petersen ER, Petersen ER, Ibsen JD, et al. Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency. Neurology. 2012;79(1):102–3.
72. Viste R, Soosai J, Vikin T, Thorsby PM, Nilsen KB, Knudsen S. Long-term improvement after combined immunomodulation in early post-H1N1 vaccination narcolepsy. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e389.
73. Dauvilliers Y, Abril B, Mas E, Michel F, Tafti M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology. 2009;73(16):1333–4.
74. Sarkanen T, Alen R, Partinen M. Transient impact of rituximab in H1N1 vaccination-associated narcolepsy with severe psychiatric symptoms. Neurologist. 2016;21(5):85–6.
75. Lecendreux M, Berthier J, Corny J, Bourdon O, Dossier C, Delclaux C. Intravenous immunoglobulin therapy in pediatric narcolepsy: a nonrandomized, open-label, controlled, longitudinal observational study. J Clin Sleep Med. 2017;13(3):441–53.